DxS

DxS is a personalized medicine company that provides molecular diagnostics to help doctors and pharmaceutical companies select therapies for patients. DxS collaborates with pharmaceutical companies to support the development and commercialization of targeted cancer therapies by offering companion diagnostic products and services. Since its establishment in 2001, DxS has experienced significant growth and firmly established its leadership position in the field of companion diagnostics, recently securing agreements with leading healthcare companies such as Amgen, Boehringer Ingelheim, and AstraZeneca. Additionally, DxS has signed an exclusive agreement with Roche Diagnostics to distribute its diagnostic products globally.DxS offers a range of cancer mutation products, including diagnostics and assays for research purposes. The TheraScreen® series of CE-marked (IVD) diagnostic kits can identify genetic tumor mutations that affect how patients respond to cancer therapies, enabling physicians to deliver the most beneficial treatments. DxS currently manufactures two diagnostic kits: TheraScreen K-RAS and TheraScreen EGFR29. The TheraScreen: K-RAS Mutation Kit serves as a companion diagnostic for Vectibix® (Amgen) and Erbitux® (Merck KGaA) in the treatment of colorectal cancer.